Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention

Stephenson KE, Wagh K, Korber B, Barouch DH. Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. Annu Rev Immunol. 2020;38:673‐703. doi:10.1146/annurev-immunol-080219-023629

Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor

Dussupt V, Sankhala RS, Gromowski GD, et al. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. Nat Med. 2020;26(2):228‐235. doi:10.1038/s41591-019-0746-2

Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial

Stephenson KE, Wegmann F, Tomaka F, et al. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22) [published online ahead of print, 2020 Feb 17] [published correction appears in Lancet HIV. 2020 Feb 28;:]. Lancet HIV. 2020;S2352-3018(20)30001-1. doi:10.1016/S2352-3018(20)30001-1

HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design.

Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH*, Korber B*. HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design. Cell Host Microbe 2019; 25:59-72.

Zika virus vaccines.

Abbink P, Stephenson KE, Barouch DH. Zika virus vaccines. Nat Rev Microbiol. 2018 Oct;16(10):594-600. doi: 10.1038/s41579-018-0039-7. Review. PubMed PMID: 29921914; PubMed Central PMCID: PMC6162149.

Therapeutic vaccination for HIV: hopes and challenges.

Stephenson KE. Therapeutic vaccination for HIV: hopes and challenges. Curr Opin HIV AIDS. 2018 Sep;13(5):408-415. doi: 10.1097/COH.0000000000000491. Review. PubMed PMID: 29957615.

Similar epitope specificities of IgG and IgA antibodies elicited by Ad26 vector prime, Env protein boost immunizations in rhesus monkeys.

Kang ZH, Bricault CA, Borducchi EN, Stephenson KE, Seaman MS, Pau M, Schuitemaker H, van Manen D, Wegmann F, Barouch DH. Similar epitope specificities of IgG and IgA antibodies elicited by Ad26 vector prime, Env protein boost immunizations in rhesus monkeys. J. Virol. 2018; 92:e00537-18.

Persistence of endothelial thrombomodulin in a patient with infectious purpura fulminans treated with protein C concentrate.

Bendapudi PK, Robbins A, LeBoeuf N, Pozdnyakova O, Bhatt A, Duke F, Sells R, McQuiston J, Humrighouse B, Rouaisnel B, Colling M, Stephenson KE, Saavedra A, Losman JA. Persistence of endothelial thrombomodulin in a patient with infectious purpura fulminans treated with protein C concentrate. Blood Adv. 2018 Nov 13;2(21):2917-2921. doi: 10.1182/bloodadvances.2018024430. PubMed PMID: 30396911; PubMed Central PMCID: PMC6234356.

NL. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.

Modjarrad K, Lin L, George SL, Stephenson KE, Eckels KH, De La Barrera RA, Jarman RG, Sondergaard E, Tennant J, Ansel JL, Mills K, Koren M, Robb ML, Barrett J, Thompson J, Kosel AE, Dawson P, Hale A, Tan CS, Walsh SR, Meyer KE, Brien J, Crowell TA, Blazevic A, Mosby K, Larocca RA, Abbink P, Boyd M, Bricault CA, Seaman MS, Basil A, Walsh M, Tonwe V, Hoft DF, Thomas SJ, Barouch DH, Michael NL. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet. 2018 Feb 10;391(10120):563-571. doi: 10.1016/S0140-6736(17)33106-9. Epub 2017 Dec 5. PubMed PMID: 29217375; PubMed Central PMCID: PMC5884730.

Neutralizing antibody responses following long-term vaccination with HIV-1 Env gp140 in guinea pigs.

Bricault CA, Kovacs JM, Badamchi-Zadeh A, McKee K, Shields JL, Gunn BM, Neubauer GH, Ghantous F, Jennings J, Gillis L, Perry J, Nkolola JP, Alter G, Chen B, Stephenson KE, Doria-Rose N, Mascola JR, Seaman MS, Barouch DH. Neutralizing antibody responses following long-term vaccination with HIV-1 Env gp140 in guinea pigs. J. Virol. 2018; 92:e00369-18.